ALPMY Overview
Upcoming Projects (ALPMY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (ALPMY)
-
Third View: Discussing Astellas Pharmaceutical's Recent FDA Listing of DIGITIVA for the Management of Heart Failure.
Ticker: ALPMY
Executed On: Nov 05, 2024 at 12:00 PM EST -
Second View: Discussing Astellas Pharmaceutical's Recent FDA Listing of DIGITIVA for the Management of Heart Failure.
Ticker: ALPMY
Executed On: Oct 18, 2024 at 11:30 AM EDT -
Discussing Astellas Pharmaceutical's Recent FDA Listing of DIGITIVA for the Management of Heart Failure.
Ticker: ALPMY
Executed On: Oct 16, 2024 at 12:30 PM EDT -
A Third Look: Discussing the standard of care for treating women with hot flashes due to menopause and the use of Veozah (fezolinetant).
Ticker: ALPMY
Executed On: Aug 28, 2024 at 04:30 PM EDT -
A Second Look: Discussing the standard of care for treating women with hot flashes due to menopause and the use of Veozah (fezolinetant).
Ticker: ALPMY
Executed On: Aug 14, 2024 at 02:45 PM EDT -
Discussing the standard of care for treating women with hot flashes due to menopause and the use of Veozah (fezolinetant).
Ticker: ALPMY
Executed On: Aug 13, 2024 at 05:00 PM EDT -
A Third Look: Discussing the potential of Pfizer and Astellas' XTANDI which was recently approved by U.S. FDA in earlier prostate cancer treatment based on the Phase 3 EMBARK trial
Tickers: PFE, ALPMY
Executed On: Dec 11, 2023 at 12:00 PM EST -
A Second Look: Discussing the potential of Pfizer and Astellas' XTANDI which was recently approved by U.S. FDA in earlier prostate cancer treatment based on the Phase 3 EMBARK trial
Tickers: PFE, ALPMY
Executed On: Dec 05, 2023 at 09:00 AM EST -
Discussing the potential of Pfizer and Astellas' XTANDI which was recently approved by U.S. FDA in earlier prostate cancer treatment based on the Phase 3 EMBARK trial
Tickers: PFE, ALPMY
Executed On: Nov 29, 2023 at 12:00 PM EST -
A Third Look: Checking in with a prescriber of Astellas Pharma's VEOZAH (fezolinetant) for hot flashes due to menopause.
Ticker: ALPMY
Executed On: Nov 09, 2023 at 07:30 AM EST -
A third look at the standard of care and the 24 month topline result of Iveric Bio's FDA Approved IZERVAY (avacincaptad pegol intravitreal solution) to treat Geographic Atrophy
Tickers: ALPMY, APLS, ISEE
Executed On: Nov 08, 2023 at 04:00 PM EST -
A Second Look: Checking in with a prescriber of Astellas Pharma's VEOZAH (fezolinetant) for hot flashes due to menopause.
Ticker: ALPMY
Executed On: Nov 06, 2023 at 05:00 PM EST -
Checking in with a prescriber of Astellas Pharma's VEOZAH (fezolinetant) for hot flashes due to menopause.
Ticker: ALPMY
Executed On: Nov 01, 2023 at 04:45 PM EDT -
A second look at the standard of care and the 24 month topline result of Iveric Bio's FDA Approved IZERVAY (avacincaptad pegol intravitreal solution) to treat Geographic Atrophy
Tickers: ALPMY, ISEE, APLS
Executed On: Sep 28, 2023 at 02:30 PM EDT -
A look at the standard of care and the 24 month topline result of Iveric Bio's FDA Approved IZERVAY (avacincaptad pegol intravitreal solution) to treat Geographic Atrophy
Tickers: ALPMY, ISEE, APLS
Executed On: Sep 28, 2023 at 10:35 AM EDT -
A third look: Discussing the potential of Astellas Pharma's VEOZAH (fezolinetant) for vasomotor symptoms (VMS) due to menopause.
Ticker: ALPMY
Executed On: May 31, 2023 at 05:00 PM EDT -
A second look: Discussing the potential of Astellas Pharma's VEOZAH (fezolinetant) for vasomotor symptoms (VMS) due to menopause.
Ticker: ALPMY
Executed On: May 31, 2023 at 07:30 AM EDT -
Discussing the potential of Astellas Pharma's VEOZAH (fezolinetant) for vasomotor symptoms (VMS) due to menopause.
Ticker: ALPMY
Executed On: May 17, 2023 at 10:00 AM EDT -
A First Look at Phase 3 Trial Data treating Gastrophageal Junction Cancer
Ticker: ALPMY
Executed On: Mar 24, 2023 at 11:00 AM EDT -
Examining the potential of Astellas’ fezolinetant as a treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
Ticker: ALPMY
Executed On: Oct 17, 2022 at 04:30 PM EDT -
A First Look at the potential of Fezolinetant as a therapy for menopause and severe vasomotor symptoms (VMS)
Ticker: ALPMY
Executed On: Sep 23, 2022 at 10:15 AM EDT
Upcoming & Overdue Catalysts (ALPMY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (ALPMY)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
